1/27, 5:04 PM (Source: TeleTrader)
more TeleTrader news


Chart for: Pfizer Inc

EMA gives conditional authorization for Paxlovid

The European Medicines Agency's (EMA) human medicines committee (CHMP) suggested giving a conditional marketing authorization for Pfizer's Paxlovid, an antiviral medicine for the treatment of COVID-19. EMA recommended prescribing Paxlovid in cases that do not require supplemental oxygen and where there is a risk of a severe escalation of symptoms.

The CHMP relied on data from a COVID-19 study showing that Paxlovid significantly reduced hospitalizations and deaths in patients who, due to an underlying condition, were at a higher risk of developing severe coronavirus symptoms.

Paxlovid's safety of use was determined to be reassuring, with little to no side effects. However, ritonavir, one of the main components of the medicine, is known to alter the effects of various other medications, due to which specific use warnings have been added to Paxlovid's product information.

Baha Breaking the News (BBN) / SP